<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS: Cardiac remodelling in <z:mp ids='MP_0002055'>diabetes</z:mp> includes pathological accumulation of extracellular matrix and myocyte <z:mpath ids='MPATH_159'>hypertrophy</z:mpath> that contribute to heart dysfunction </plain></SENT>
<SENT sid="1" pm="."><plain>Attenuation of remodelling represents a potential therapeutic target </plain></SENT>
<SENT sid="2" pm="."><plain>We tested this hypothesis using a new anti-fibrotic drug, FT011 (Fibrotech Therapeutics Pty Ltd), on diabetic Ren-2 rats, a model which replicates many of the structural and functional manifestations of diabetic <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> in humans </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS AND RESULTS: Homozygous Ren-2 rats were randomized to receive <z:chebi fb="1" ids="9288">streptozotocin</z:chebi> or vehicle then further randomized to FT011 (200 mg/kg/day) or vehicle treatment for 6 weeks </plain></SENT>
<SENT sid="4" pm="."><plain>Prior to tissue collection, cardiac function was assessed via echocardiography and cardiac catheterization </plain></SENT>
<SENT sid="5" pm="."><plain>Total collagen deposition and cardiomyocyte <z:mpath ids='MPATH_159'>hypertrophy</z:mpath> were assessed by picrosirius red and <z:chebi fb="1" ids="51686">haematoxylin</z:chebi> and eosin staining, respectively </plain></SENT>
<SENT sid="6" pm="."><plain>Macrophage interstitial infiltration and type I and III collagen were quantitated by immunostaining </plain></SENT>
<SENT sid="7" pm="."><plain>Without affecting blood pressure or <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e>, treatment of diabetic rats with FT011 significantly attenuated interstitial <z:mp ids='MP_0003045'>fibrosis</z:mp> (total collagen, 5.09 ±1.28 vs, 2.42 ±0.43%/area; type I collagen, 4.09 ±1.16 vs. 1.42 ±0.38%/area; type III collagen, 1.52 ±0.33 vs. 0.71 ±0.14 %/area; P &lt; 0.05), cardiomyocyte <z:mpath ids='MPATH_159'>hypertrophy</z:mpath> (882 ±38 vs. 659 ±28 µm(2); P &lt; 0.05), and interstitial macrophage influx (66 ±5.3 vs, 44 ±7.9 number/section; P &lt; 0.05) </plain></SENT>
<SENT sid="8" pm="."><plain>Cardiac myopathic <z:mpath ids='MPATH_66'>dilatation</z:mpath> was normalized, as evidenced by reduced left ventricular inner diameter at diastole (0.642 ±0.016 vs. 0.577 ±0.024 cm), increased ejection fraction (75 ±1.1 vs. 83 ±1.2%) and preload recruitable <z:hpo ids='HP_0001297'>stroke</z:hpo> work relationship (44 ±6.7 vs. 77 ±6.3 slope-mmHg; P &lt; 0.05), and reduced end-diastolic pressure-volume relationship (0.059 ±0.011 vs. 0.02 ±0.003 slope-mmHg/μL; P &lt; 0.05) </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: A direct anti-fibrotic agent, FT011, attenuates cardiac remodelling and dysfunction in experimental diabetic <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>This represents a novel therapy for the treatment of diabetic <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> associated with <z:mp ids='MP_0003141'>cardiac fibrosis</z:mp> and <z:mpath ids='MPATH_159'>hypertrophy</z:mpath> </plain></SENT>
</text></document>